Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members

Summary

This pilot clinical trial studies different types of energy balance interventions to see how well they work in increasing the physical activity levels of breast cancer gene-positive patients, Lynch syndrome-positive patients, chronic lymphocytic leukemia (CLL) survivors or family members of cancer survivors who are at high risk for cancer. Increasing exercise and eating healthy foods may help reduce the risk of cancer. Studying how well different types of interventions work in motivating cancer survivors or high-risk family members to increase exercise and healthy food choices may help doctors plan the most effective motivational program for cancer prevention.

Conditions

• Body Mass Index 25 or Greater
• BRCA1 Gene Mutation
• BRCA2 Gene Mutation
• Breast Carcinoma
• Cancer Survivor
• Chronic Lymphocytic Leukemia
• Fatigue
• Health Status Unknown
• Lynch Syndrome
• Ovarian Carcinoma
• Overweight

Interventions

DIETARY_SUPPLEMENT

Dietary Intervention

Record dietary intake 4-7 days per week

DIETARY_SUPPLEMENT

Dietary Intervention

Record dietary intake 1 day per week

OTHER

Internet-Based Intervention

Receive email coaching

OTHER

Internet-Based Intervention

Participate in social networking

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

BEHAVIORAL

Telephone-Based Intervention

Receive telephone coaching

BEHAVIORAL

Telephone-Based Intervention

Receive text messages

Sponsors & Collaborators

• M.D. Anderson Cancer Center

  lead OTHER

• National Cancer Institute (NCI)

  collaborator NIH

Principal Investigators

• Karen M Basen-Engquist · M.D. Anderson Cancer Center

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2014-09-17

Primary Completion

2027-09-30

Completion

2027-09-30

FDA Drug

Yes

Countries

• United States

Study Locations